1. Resources
  2. Citations Library

Citation Details

You are viewing citation details. You can save or export citation(s) below, access an article, or start a new search.

281–290 of 499 records found matching your query:
Search
Show Filter Hide Filter
<< < Back 21 22 23 24 25 26 27 28 29 30 Next > >>    
Back to Search
Select All  |  Deselect All
List View  | Details print

Headers act as filters

  •  
  • Records
      1. Author :
        Scatena, Caroline D; Hepner, Mischa A; Oei, Yoko A; Dusich, Joan M; Yu, Shang-Fan; Purchio, Tony; Contag, Pamela R; Jenkins, Darlene E
      2. Title :
        Imaging of bioluminescent LNCaP-luc-M6 tumors: a new animal model for the study of metastatic human prostate cancer
      3. Type :
        Journal Article
      4. Year :
        2004
      5. Publication :
        The Prostate
      6. Products :

        Bioware cell lines

      7. Volume :
        59
      8. Issue :
        3
      9. Page Numbers :
        N/A
      10. Research Area :
        N/A
      11. Keywords :
        Animals; Bioware; Disease Models, Animal; Humans; LnCaP-luc cells; Luciferases; Luminescent Measurements; Male; Mice; Mice, SCID; Neoplasm Metastasis; Phenotype; Plasmids; Prostatic Neoplasms; Transfection; Transplantation, Heterologous; Tumor Cells, Cultured
      12. Abstract :
        BACKGROUND Animal experiments examining hormone-sensitive metastatic prostate cancer using the human LNCaP cell line have been limited to endpoint analyses. To permit longitudinal studies, we generated a luciferase-expressing cell line and used bioluminescent imaging (BLI) to non-invasively monitor the in vivo growth of primary LNCaP tumors and metastasis. METHODS LNCaP.FGC cells were transfected to constitutively express firefly luciferase. LNCaP-luc-M6 cells were tested for bioluminescent signal intensity and hormone responsiveness in vitro. The cells were implanted in subcutaneous and orthotopic sites in SCID-bg mice and imaged over time. RESULTS The LNCaP-luc-M6 cells formed subcutaneous and orthotopic tumors in SCID-bg mice, and nearly all tumor-bearing animals developed pulmonary metastases. Early detection and temporal growth of primary tumors and metastatic lesions was successfully monitored by BLI. CONCLUSIONS The LNCaP-luc-M6 cell line is a bioluminescent, hormone-sensitive prostate cancer cell line applicable for BLI studies to non-invasively monitor subcutaneous and orthotopic prostate tumor growth and metastasis in vivo.
      13. URL :
        http://www.ncbi.nlm.nih.gov/pubmed/15042605
      14. Call Number :
        PKI @ catherine.lautenschlager @
      15. Serial :
        9015
      1. Author :
        Hunter, John J.; Neben, Tamlyn Yee; Purchio, Tony; Jenkins, Darlene
      2. Title :
        Bioluminescent monitoring of ovarian carcinoma growth and spread in mouse xenograft tumor models
      3. Type :
        Journal Article
      4. Year :
        2005
      5. Publication :
        AACR Meeting Abstracts
      6. Products :

        Bioware cell lines

      7. Volume :
        2005
      8. Issue :
        1
      9. Page Numbers :
        N/A
      10. Research Area :
        N/A
      11. Keywords :
        Bioware; SKOV3-luc-D3 cells
      12. Abstract :
        Peritoneal dissemination is a common feature of human ovarian carcinoma. While this can be mimicked in preclinical models by intraperitoneal injection of human ovarian tumor cells into immunocompromised mice, the resulting tumor burden is difficult to monitor and quantify. Intraperitoneal tumor growth is typically evaluated indirectly by measured changes in mouse abdominal girth and body weight or, directly, by macroscopic and histological examination at the endpoint of the study. In order to establish a model system that allows continuous and accurate assessment of ovarian cancer growth and spread over time we transfected SKOV-3 cells with the firefly luciferase gene. The resulting cell line, SKOV3-luc-D3, expresses stable levels of luciferase in vitro and emits a strong luminescent signal when exposed to luciferin. Xenograft tumors established with this cell line can be tracked and quantified non-invasively by bioluminescent imaging using a highly sensitive, cooled CCD camera (IVIS(R) Imaging System, Xenogen Corp). In addition to providing a direct measure of primary tumor burden and growth, the SKOV3-luc-D3 cell line also allows for real-time evaluation of tumor response to various therapeutic agents, as well as enhanced detection of distal metastases.
      13. URL :
        http://www.aacrmeetingabstracts.org/cgi/content/abstract/2005/1/256-b
      14. Call Number :
        PKI @ catherine.lautenschlager @
      15. Serial :
        9014
      1. Author :
        Xiao, Kai; Luo, Juntao; Fowler, Wiley L; Li, Yuanpei; Lee, Joyce S; Xing, Li; Cheng, R Holland; Wang, Li; Lam, Kit S
      2. Title :
        A self-assembling nanoparticle for paclitaxel delivery in ovarian cancer
      3. Type :
        Journal Article
      4. Year :
        2009
      5. Publication :
        Biomaterials
      6. Products :

        Bioware cell lines

      7. Volume :
        30
      8. Issue :
        30
      9. Page Numbers :
        N/A
      10. Research Area :
        N/A
      11. Keywords :
        Albumins; Animals; Antineoplastic Agents; Biocompatible Materials; Bioware; Cell Line, Tumor; Drug Delivery Systems; Emulsifying Agents; Female; Humans; Male; Maximum Tolerated Dose; Mice; Mice, Nude; Nanoparticles; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; SKOV3-luc-D3 cells; Spectroscopy, Near-Infrared
      12. Abstract :
        Paclitaxel (PTX) is one of the most effective chemotherapeutic drugs for the treatment of a variety of cancers. However, it is associated with serious side effects caused by PTX itself and the Cremophor EL emulsifier. In the present study, we report the development of a well-defined amphiphilic linear-dendritic copolymer (named as telodendrimer) composed of polyethylene glycol (PEG), cholic acid (CA, a facial amphiphilic molecule) and lysine, which can form drug-loaded core/shell micelles when mixed with hydrophobic drug, such as PTX, under aqueous condition. We have used PEG(5k)-CA(8), a representive telodendrimer, to prepare paclitaxel-loaded nanoparticles (PTX-PEG(5k)-CA(8) NPs) with high loading capacity (7.3 mg PTX/mL) and a size of 20-60 nm. This novel nanoformulation of PTX was found to exhibit similar in vitro cytotoxic activity against ovarian cancer cells as the free drug (Taxol) or paclitaxel/human serum albumin nanoaggregate (Abraxane). The maximum tolerated doses (MTDs) of PTX-PEG(5k)-CA(8) NPs after single dose and five consecutive daily doses in mice were approximately 75 and 45 mg PTX/kg, respectively, which were 2.5-fold higher than those of Taxol. In both subcutaneous and orthotopic intraperitoneal murine models of ovarian cancer, PTX-PEG(5k)-CA(8) NPs achieved superior toxicity profiles and anti-tumor effects compared to Taxol and Abraxane at equivalent PTX doses, which were attributed to their preferential tumor accumulation, and deep penetration into tumor tissue, as confirmed by near infrared fluorescence (NIRF) imaging.
      13. URL :
        http://www.ncbi.nlm.nih.gov/pubmed/19660809
      14. Call Number :
        PKI @ catherine.lautenschlager @
      15. Serial :
        9013
      1. Author :
        Cirstoiu-Hapca, A; Buchegger, F; Lange, N; Bossy, L; Gurny, R; Delie, F
      2. Title :
        Benefit of anti-HER2-coated paclitaxel-loaded immuno-nanoparticles in the treatment of disseminated ovarian cancer: Therapeutic efficacy and biodistribution in mice
      3. Type :
        Journal Article
      4. Year :
        2010
      5. Publication :
        Journal of controlled release: official journal of the Controlled Release Society
      6. Products :

        Bioware cell lines

      7. Volume :
        144
      8. Issue :
        3
      9. Page Numbers :
        N/A
      10. Research Area :
        N/A
      11. Keywords :
        Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Bioware; Cell Line, Tumor; Drug Carriers; Female; Humans; Mice; Nanoparticles; Ovarian Neoplasms; Paclitaxel; Receptor, erbB-2; SKOV3-luc-D3 cells; Tissue Distribution; Xenograft Model Antitumor Assays
      12. Abstract :
        The benefit of polymeric immuno-nanoparticles (NPs-Tx-HER), consisting of paclitaxel (Tx)-loaded nanoparticles coated with anti-HER2 monoclonal antibodies (Herceptin, trastuzumab), in cancer treatment was assessed in a disseminated xenograft ovarian cancer model induced by intraperitoneal inoculation of SKOV-3 cells overexpressing HER2 antigens. The study was focused on the evaluation of therapeutic efficacy and biodistribution of NPs-Tx-HER compared to other Tx formulations. The therapeutic efficacy was determined by two methods: bioluminescence imaging and survival rate. The treatment regimen consisted in an initial dose of 20mg/kg Tx administered as 10mg/kg intravenously (IV) and 10mg/kg intraperitonealy (IP), followed by five alternative IP and IV injections of 10mg/kg Tx every 3 days. The bioluminescence study has clearly shown the superior anti-tumor activity of NPs-Tx-HER compared to free Tx. As a confirmation of these results, a significantly longer survival of mice was observed for NPs-Tx-HER treatment compared to free Tx, Tx-loaded nanoparticles coated with an irrelevant mAb (Mabthera, rituximab) or Herceptin alone, indicating the potential of immuno-nanoparticles in cancer treatment. The biodistribution pattern of Tx was assessed on healthy and tumor bearing mice after IV or IP administration. An equivalent biodistribution profile was observed in healthy mice for Tx encapsulated either in uncoated nanoparticles (NPs-Tx) or in NPs-Tx-HER. No significant difference in Tx biodistribution was observed after IV or IP injection, except for a lower accumulation in the lungs when NPs were administered by IP. Encapsulated Tx accumulated in the organs of the reticulo-endothelial system (RES) such as the liver and spleen, whereas free Tx had a non-specific distribution in all tested organs. Compared to free Tx, the single dose injection (IV or IP) of encapsulated Tx in mice bearing tumors induced a higher tumor accumulation. However, no difference in overall tumor accumulation between NPs-Tx-HER and NPs-Tx was observed. In conclusion, the encapsulation of Tx into NPs-Tx-HER immuno-nanoparticles resulted in an improved efficacy of drug in the treatment of disseminated ovarian cancer overexpressing HER2 receptors.
      13. URL :
        http://www.ncbi.nlm.nih.gov/pubmed/20219607
      14. Call Number :
        PKI @ catherine.lautenschlager @
      15. Serial :
        9012
      1. Author :
        Jenkins, Darlene E.; Hornig, Yvette S.; Oei, Yoko A.; Yu, Shang-Fan; Dusich, Joan M.; Jenkins, Darlene E.; Purchio, Tony; Hornig, Yvette S.; Oei, Yoko A.; Yu, Shang-Fan; Dusich, Joan M.; Purchio, Tony
      2. Title :
        Luciferase-expressing MCF-7-luc-F5 human breast cancer cells used to monitor mammary fat pad tumor growth and metastasis in vivo in nude-beige mice
      3. Type :
        Journal Article
      4. Year :
        2004
      5. Publication :
        AACR Meeting Abstracts
      6. Products :

        Bioware cell lines

      7. Volume :
        2004
      8. Issue :
        1
      9. Page Numbers :
        N/A
      10. Research Area :
        N/A
      11. Keywords :
        Bioware; MCF-7-luc-F5 cells
      12. Abstract :
        A clonal human tumor cell line expressing firefly luciferase, MCF-7-luc-F5, was developed from parental MCF-7 breast carcinoma cells and characterized for bioluminescence in vitro and in vivo. As few as twenty cells were detectable in vitro and average bioluminescence measured approximately 680 photons/sec/cell. Tumorigenesis of MCF-7-luc-F5 cells was assessed with and without estrogen supplement in vivo following injection of cells into the mammary fat pad of nude-beige mice. Continuous tumor growth was observed by weekly bioluminescent imaging in mice receiving a slow release (60 day) estrogen pellet implant (0.36 mg/pellet), while no tumor growth occurred in mice without estrogen supplement. Caliper measurements of tumor volume indicated similar results. A kinetic analysis of luciferase activity in vivo demonstrated that peak signals were evident approximately 12-15 minutes after injection of luciferin substrate and were maintained at a relatively stable level for at least another 20-25 minutes. Spontaneous metastasis from the primary mammary fat pad tumor to thoracic and axillary regions was observed in vivo in 50% of the animals. Subsequent ex vivo images and histology identified metastatic sites in lung, rib, or lymph nodes depending on the mouse. Standard drug treatment on primary and secondary tumor growth was also monitored by bioluminescent imaging.
      13. URL :
        http://www.aacrmeetingabstracts.org/cgi/content/abstract/2004/1/1179-c
      14. Call Number :
        PKI @ catherine.lautenschlager @
      15. Serial :
        9011
      1. Author :
        Mitchell, Dianne; Pobre, Eileen G; Mulivor, Aaron W; Grinberg, Asya V; Castonguay, Roselyne; Monnell, Travis E; Solban, Nicolas; Ucran, Jeffrey A; Pearsall, R Scott; Underwood, Kathryn W; Seehra, Jasbir; Kumar, Ravindra
      2. Title :
        ALK1-Fc inhibits multiple mediators of angiogenesis and suppresses tumor growth
      3. Type :
        Journal Article
      4. Year :
        2010
      5. Publication :
        Molecular cancer therapeutics
      6. Products :

        Bioware cell lines

      7. Volume :
        9
      8. Issue :
        2
      9. Page Numbers :
        N/A
      10. Research Area :
        N/A
      11. Keywords :
        Activin Receptors, Type II; Animals; Bioware; Bone Morphogenetic Proteins; CHO Cells; Cricetinae; Cricetulus; Endothelial Cells; Endothelium, Vascular; Growth Differentiation Factor 2; Humans; MCF-7-luc-F5 cells; Mice; Neoplasms; Neovascularization, Pathologic; Surface Plasmon Resonance; Telangiectasia, Hereditary Hemorrhagic
      12. Abstract :
        Activin receptor-like kinase-1 (ALK1) is a type I, endothelial cell-specific member of the transforming growth factor-beta superfamily of receptors known to play an essential role in modulating angiogenesis and vessel maintenance. In the present study, we sought to examine the angiogenic and tumorigenic effects mediated upon the inhibition of ALK1 signaling using a soluble chimeric protein (ALK1-Fc). Of 29 transforming growth factor-beta-related ligands screened by surface plasmon resonance, only bone morphogenetic protein (BMP9) and BMP10 displayed high-affinity binding to ALK1-Fc. In cell-based assays, ALK1-Fc inhibited BMP9-mediated Id-1 expression in human umbilical vein endothelial cells and inhibited cord formation by these cells on a Matrigel substrate. In a chick chorioallantoic membrane assay, ALK1-Fc reduced vascular endothelial growth factor-, fibroblast growth factor-, and BMP10-mediated vessel formation. The growth of B16 melanoma explants was also inhibited significantly by ALK1-Fc in this assay. Finally, ALK1-Fc treatment reduced tumor burden in mice receiving orthotopic grafts of MCF7 mammary adenocarcinoma cells. These data show the efficacy of chimeric ALK1-Fc proteins in mitigating vessel formation and support the view that ALK1-Fc is a powerful antiangiogenic agent capable of blocking vascularization.
      13. URL :
        http://www.ncbi.nlm.nih.gov/pubmed/20124460
      14. Call Number :
        PKI @ catherine.lautenschlager @
      15. Serial :
        9010
      1. Author :
        Peter, Christoph; Kielstein, Jan T; Clarke-Katzenberg, Regina; Adams, M Christopher; Pitsiouni, Maria; Kambham, Neeraja; Karimi, Mobin A; Kengatharan, Ken M; Cooke, John P
      2. Title :
        A novel bioluminescent tumor model of human renal cancer cell lines: an in vitro and in vivo characterization
      3. Type :
        Journal Article
      4. Year :
        2007
      5. Publication :
        The Journal of urology
      6. Products :

        Bioware cell lines

      7. Volume :
        177
      8. Issue :
        6
      9. Page Numbers :
        N/A
      10. Research Area :
        N/A
      11. Keywords :
        Animals; Bioware; carcinoma, renal cell; Cell Culture Techniques; Cell Line, Tumor; Cell Proliferation; Firefly Luciferin; HT-29-luc-D6 cells; Humans; Kidney Neoplasms; Luminescence; Luminescent Agents; Male; Mice; Mice, SCID; Models, Biological; Tumor Burden
      12. Abstract :
        PURPOSE Bioluminescent imaging permits sensitive in vivo detection and quantification of cells engineered to emit light. We developed a bioluminescent human renal cancer cell line for in vitro and in vivo studies. MATERIAL AND METHODS The 2 human renal cell carcinoma cell lines SN12-C and SN12-L1 were stably transfected to constitutively express luciferase using a retroviral shuttle. The bioluminescent signal was correlated with tumor cell numbers in vitro. Parental and transfected cells were compared by growth kinetics and histology. Tumor burden after heterotopic injection in immune deficient mice was monitored up to 39 days. The kinetics of the bioluminescent signal was evaluated for 1 to 60 minutes following luciferin injection. RESULTS Bioengineered renal cancer cell lines stably expressed luciferase. The growth kinetics of the cells in vitro and the histology of tumors resulting from implantation of these cells were unaffected by retroviral transfection with the luciferase gene. As few as 1,000 cells could be reliably detected. The intensity of the bioluminescent signal correlated with the number of tumor cells in vitro. Photon emission in vivo and ex vivo correlated significantly with tumor weight at sacrifice. After intraperitoneal injection of luciferin there was a time dependent change in the intensity of the bioluminescent signal with maximum photon emission at 20 minutes (optimal 17 to 25). CONCLUSIONS Luciferase transfected human renal cancer lines allow reliable, rapid, noninvasive and longitudinal monitoring of tumor growth in vivo. The ability to assess tumor development in vivo with time is economical and effective compared to end point data experiments.
      13. URL :
        http://www.ncbi.nlm.nih.gov/pubmed/17509355
      14. Call Number :
        PKI @ catherine.lautenschlager @
      15. Serial :
        9009
      1. Author :
        Razavi, Reza; Harrison, Lawrence E
      2. Title :
        Thermal sensitization using induced oxidative stress decreases tumor growth in an in vivo model of hyperthermic intraperitoneal perfusion
      3. Type :
        Journal Article
      4. Year :
        2010
      5. Publication :
        Annals of surgical oncology
      6. Products :

        Bioware cell lines

      7. Volume :
        17
      8. Issue :
        1
      9. Page Numbers :
        N/A
      10. Research Area :
        N/A
      11. Keywords :
        Animals; Bioware; Carcinoma; Cell Proliferation; Colonic Neoplasms; DNA Damage; Drug Therapy, Combination; Female; HT-29-luc-D6 cells; Humans; Hydrogen peroxide; Hyperthermia, Induced; Injections, Intraperitoneal; Mice; Mice, Nude; Oxidants; Oxidative Stress; Survival Rate; tert-Butylhydroperoxide; Treatment Outcome; Tumor Cells, Cultured
      12. Abstract :
        BACKGROUND The purpose of this study was to extend our in vitro observations that induced oxidative stress under hyperthermic conditions decreases tumor cell growth into a preclinical murine model of hyperthermic perfusion. METHODS A nude mouse model of colon cancer carcinomatosis with HT-29-Luc-D6 colon cancer cells was established, and tumor growth was measured by serial bioluminescent imaging. RESULTS By means of a survival model of hyperthermic perfusion, we demonstrated that perfusion with normothermic saline decreased tumor growth compared with no perfusion controls, and tumor growth was further decreased with hyperthermic perfusion alone. The induction of oxidative stress with hydrogen peroxide in the perfusate at concentrations as high as 600 microM was well tolerated in this model of hyperthermic perfusion. Importantly, induced oxidative stress using hydrogen peroxide under hyperthermic conditions significantly decreased in vivo tumor cell growth compared with all other controls. CONCLUSIONS On the basis of our observations, thermal sensitization through modulation of cellular oxidative stress may represent a novel approach to increase the efficacy of hyperthermia as an anticancer modality.
      13. URL :
        http://www.ncbi.nlm.nih.gov/pubmed/19711132
      14. Call Number :
        PKI @ catherine.lautenschlager @
      15. Serial :
        9008
      1. Author :
        Cabral, Horacio; Nishiyama, Nobuhiro; Kataoka, Kazunori
      2. Title :
        Optimization of (1,2-diamino-cyclohexane)platinum(II)-loaded polymeric micelles directed to improved tumor targeting and enhanced antitumor activity
      3. Type :
        Journal Article
      4. Year :
        2007
      5. Publication :
        Journal of controlled release: official journal of the Controlled Release Society
      6. Products :

        Bioware cell lines

      7. Volume :
        121
      8. Issue :
        3
      9. Page Numbers :
        N/A
      10. Research Area :
        N/A
      11. Keywords :
        Animals; Antineoplastic Agents; Bioware; Cell Line, Tumor; Drug Carriers; Drug Delivery Systems; Female; Hela Cells; HeLa-luc; Humans; Mice; Mice, SCID; Micelles; Neoplasms; Organoplatinum Compounds; Platinum; Polymers; Xenograft Model Antitumor Assays
      12. Abstract :
        Polymeric micelles are promising nanocarriers, which might enhance the efficacy of antitumor drugs. Herein, polymeric micelles incorporating dichloro(1,2-diamino-cyclohexane)platinum(II) (DACHPt), the oxaliplatin parent complex, were prepared through the polymer-metal complex formation of DACHPt with poly(ethylene glycol)-b-poly(glutamic acid) [PEG-b-P(Glu)] block copolymer having different lengths of the poly(glutamic acid) block [p(Glu): 20, 40, and 70 U]. The resulting micelles were studied with the aim of optimizing the system's biological performance. DACHPt-loaded micelles (DACHPt/m) were approximately 40 nm in diameter and had a narrow size distribution. In vivo biodistribution and antitumor activity experiments (CDF1 mice bearing the murine colon adenocarcinoma C-26 inoculated subcutaneously) showed 20-fold greater accumulation of DACHPt/m at the tumor site than free oxaliplatin to achieve substantially higher antitumor efficacy. Moreover, the micelles prepared from PEG-b-P(Glu) with 20 U of P(Glu) exhibited the lowest non-specific accumulation in the liver and spleen to critically reduce non-specific accumulation, resulting in higher specificity to solid tumors. The antitumor effect of DACHPt/m was also evaluated on multiple metastases generated from intraperitoneally injected bioluminescent HeLa (HeLa-Luc) cells. The in vivo bioluminescent data indicated that DACHPt/m decreased the signal 10-to 50-fold compared to the control indicating a very strong antitumor activity. These results suggest that DACHPt/m could be an outstanding drug delivery system for oxaliplatin in the treatment of solid tumors.
      13. URL :
        http://www.ncbi.nlm.nih.gov/pubmed/17628162
      14. Call Number :
        PKI @ catherine.lautenschlager @
      15. Serial :
        9007
      1. Author :
        Shimomura, Toshiyasu; Hasako, Shinichi; Nakatsuru, Yoko; Mita, Takashi; Ichikawa, Koji; Kodera, Tsutomu; Sakai, Takumi; Nambu, Tadahiro; Miyamoto, Mayu; Takahashi, Ikuko; Miki, Satomi; Kawanishi, Nobuhiko; Ohkubo, Mitsuru; Kotani, Hidehito; Iwasawa, Yoshikazu
      2. Title :
        MK-5108, a highly selective Aurora-A kinase inhibitor, shows antitumor activity alone and in combination with docetaxel
      3. Type :
        Journal Article
      4. Year :
        2010
      5. Publication :
        Molecular cancer therapeutics
      6. Products :

        Bioware cell lines

      7. Volume :
        9
      8. Issue :
        1
      9. Page Numbers :
        N/A
      10. Research Area :
        N/A
      11. Keywords :
        Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bioware; Cell Death; Cell Line, Tumor; Cell Proliferation; Cyclohexanecarboxylic Acids; HeLa-luc; Humans; Inhibitory Concentration 50; Mice; Mitosis; Protein kinase inhibitors; Protein-Serine-Threonine Kinases; Rats; Taxoids; Thiazoles; Xenograft Model Antitumor Assays
      12. Abstract :
        Aurora-A kinase is a one of the key regulators during mitosis progression. Aurora-A kinase is a potential target for anticancer therapies because overexpression of Aurora-A, which is frequently observed in some human cancers, results in aberrant mitosis leading to chromosomal instability and possibly tumorigenesis. MK-5108 is a novel small molecule with potent inhibitory activity against Aurora-A kinase. Although most of the Aurora-kinase inhibitors target both Aurora-A and Aurora-B, MK-5108 specifically inhibited Aurora-A kinase in a panel of protein kinase assays. Inhibition of Aurora-A by MK-5108 in cultured cells induced cell cycle arrest at the G(2)-M phase in flow cytometry analysis. The effect was confirmed by the accumulation of cells with expression of phosphorylated Histone H3 and inhibition of Aurora-A autophosphorylation by immunostaining assays. MK-5108 also induced phosphorylated Histone H3 in skin and xenograft tumor tissues in a nude rat xenograft model. MK-5108 inhibited growth of human tumor cell lines in culture and in different xenograft models. Furthermore, the combination of MK-5108 and docetaxel showed enhanced antitumor activities compared with control and docetaxel alone-treated animals without exacerbating the adverse effects of docetaxel. MK-5108 is currently tested in clinical trials and offers a new therapeutic approach to combat human cancers as a single agent or in combination with existing taxane therapies.
      13. URL :
        http://www.ncbi.nlm.nih.gov/pubmed/20053775
      14. Call Number :
        PKI @ catherine.lautenschlager @
      15. Serial :
        9006
<< < Back 21 22 23 24 25 26 27 28 29 30 Next > >>    
Back to Search
Select All  |  Deselect All
List View  | Details print